ストックスクリーナーアプリを入手
16.31
4.76%
-0.47
前日終値:
$16.78
開ける：
$16.78
24時間の取引高:
186.41K
Relative Volume:
0.24
時価総額：
$1.02B
収益：
-
当期純損益:
$-119.67M
株価収益率:
-5.9744
EPS:
-2.73
ネットキャッシュフロー:
$-97.30M
1週間 パフォーマンス:
-4.59%
1か月 パフォーマンス:
+65.10%
6か月 パフォーマンス:
+33.29%
1年 パフォーマンス:
+24.46%
1日の値動き範囲:
$15.94
$17.21
1週間の範囲:
$15.98
$17.35
52週間の値動き範囲:
$8.241
$18.38
Mineralys Therapeutics Inc Stock (MLYS) Company Profile
名前
Mineralys Therapeutics Inc
セクター
電話
(888) 378-6240
住所
150 N. RADNOR CHESTER ROAD, RADNOR
MLYS を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
MLYS
Mineralys Therapeutics Inc
|
16.30 | 1.02B | 0 | -119.67M | -97.30M | -2.73 |
|
VRTX
Vertex Pharmaceuticals Inc
|
503.52 | 131.41B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
641.90 | 72.26B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
588.05 | 35.74B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
271.70 | 35.58B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
249.85 | 27.23B | 3.81B | -644.79M | -669.77M | -6.24 |
Mineralys Therapeutics Inc Stock (MLYS) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-07-10 | 開始されました | H.C. Wainwright | Buy |
| 2024-04-02 | 開始されました | Goldman | Buy |
| 2023-03-07 | 開始されました | BofA Securities | Buy |
| 2023-03-07 | 開始されました | Credit Suisse | Outperform |
| 2023-03-07 | 開始されました | Evercore ISI | Outperform |
| 2023-03-07 | 開始されました | Guggenheim | Buy |
| 2023-03-07 | 開始されました | Stifel | Buy |
| 2023-03-07 | 開始されました | Wells Fargo | Overweight |
すべてを表示
Mineralys Therapeutics Inc (MLYS) 最新ニュース
Insiders Make Huge Purchases of These 4 Biotech Stocks - 24/7 Wall St.
Mineralys Therapeutics, Inc. (MLYS): Among Stocks Receiving the Most Insider Love in March - Insider Monkey
Mineralys Therapeutics to Host Conference Call on Advance-HTN and Launch-HTN Clinical Trial Results Featuring Dr. Luke Laffin - Nasdaq
Mineralys Therapeutics to Host KOL Call to Discuss Clinical Data from Launch-HTN and Advance-HTN Pivotal Trials Tuesday, April 1, 2025, at 8:00 AM ET - The Manila Times
Mineralys Therapeutics to Host KOL Call to Discuss Clinical - GlobeNewswire
Groundbreaking Hypertension Treatment Data: Cleveland Clinic Expert Reveals Pivotal Trial Results - StockTitan
RA CAPITAL MANAGEMENT, L.P. Increases Stake in Mineralys Therape - GuruFocus.com
Lorundrostat Shows Promise in Treatment of Uncontrolled and Resistant Hypertension in trials - Medical Dialogues
Mineralys, Tenaya, SpringWorks, COSCIENS, Metagenomi: 5 Biotech Stocks That Led Retail Follower Growth Last Week - MSN
Buy Rating Justified for Mineralys Therapeutics, Inc. Due to Promising Study Results and Manageable Safety Profile - TipRanks
Mineralys Therapeutics to Present Phase 2 Advance-HTN Trial Data at ACC.25 - MSN
Is Mineralys Therapeutics, Inc. (MLYS) a Pump and Dump Stock Favored by Hedge Funds? - Insider Monkey
Mineralys Therapeutics Announces Closing of Underwriters’ - GlobeNewswire
Mineralys Therapeutics Announces Closing of Underwriters’ Option to Purchase Additional Shares in Connection with Public Offering of Common Stock - Marketscreener.com
Mineralys Therapeutics Raises Massive $201M as Investors Back Promising Drug Development - StockTitan
10 Pump and Dump Stocks Favored by Hedge Funds - Insider Monkey
Mineralys to present hypertension drug trial results at ACC.25 By Investing.com - Investing.com Australia
Major Investment Alert: Ra Capital Management Bets Big on Mineralys Therapeutics! - TipRanks
MLYS Stock Price and Chart — NASDAQ:MLYS - TradingView
Mineralys Therapeutics Announces Data from the Phase 2 Advance-HTN Trial of Lorundrosat for the Treatment of Hypertension Has Been Accepted as a Late-Breaking Presentation at the 2025 American College of Cardiology’s Annual Scientific Session & Ex - Marketscreener.com
Largest borrow rate increases among liquid names - TipRanks
Mineralys to present hypertension drug trial results at ACC.25 - Investing.com India
Mineralys Therapeutics Announces Data from the Phase 2 Advance-HTN Trial of Lorundrosat for the Treatment of Hypertension Has Been Accepted as a Late-Breaking Presentation at the 2025 American College of Cardiology's Annual Scientific Session & Ex - The Manila Times
Mineralys Therapeutics to Present Phase 2 Trial Data on Lorundrostat for Uncontrolled Hypertension at ACC.25 - Nasdaq
Mineralys Therapeutics Announces Data from the Phase 2 - GlobeNewswire
Mineralys Therapeutics : Corporate Overview March 2025 -March 17, 2025 at 08:06 am EDT - Marketscreener.com
Major Breakthrough: New Hypertension Drug Data Earns Coveted ACC Late-Breaking Slot - StockTitan
Mineralys Therapeutics Stock (MLYS): Strategic Offering to Fuel Growth - Value the Markets
A&O Shearman advises on the USD175 million follow-on equity offering by Mineralys Therapeutics Inc. - A&O Shearman
Mineralys Therapeutics prices $175M stock offering - MSN
Mineralys Reports Positive Results for Hypertension Drug Lorundrostat - MSN
Latham & Watkins Advises Mineralys Therapeutics on US$175 Million Underwritten Public Offering of Common Stock - Latham & Watkins LLP
Biotech Alert: Searches spiking for these stocks today - TipRanks
Hello Group, loanDepot, Mineralys Therapeutics And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session - Benzinga India
Proficio Capital Partners LLC Purchases New Shares in Mineralys Therapeutics, Inc. (NASDAQ:MLYS) - Defense World
Mineralys Therapeutics Prices $175 Million Share Offering -March 12, 2025 at 03:58 am EDT - Marketscreener.com
Mineralys Therapeutics sets $13.50 share price for public offering By Investing.com - Investing.com Australia
Mineralys Therapeutics Announces Pricing of $175.0 Million Underwritten Public Offering of Common Stock - GlobeNewswire
Mineralys Therapeutics sets $13.50 share price for public offering - Investing.com
Mineralys Therapeutics Announces Pricing of $175 Million Public Offering of Common Stock - Nasdaq
Mineralys Secures Massive $175M Funding to Accelerate Breakthrough Drug Development - StockTitan
Mineralys in Radnor Sees Stock Price Explode After Hypertension Drug Test - DELCO.Today
Mineralys Therapeutics Announces Pricing Of $175.0 Million Underwritten Public Offering Of Common Stock - Marketscreener.com
Stifel maintains Buy on Mineralys Therapeutics, $45 target By Investing.com - Investing.com Australia
(MLYS) Trading Advice - Stock Traders Daily
Mineralys launches $250 mln equity offering to fund blood pressure drug; shares dip - TradingView
Pa.-based biopharma company successfully completes two trials for hypertension drug - Pennsylvania Business Report
Mineralys sees stock surge on lorundrostat data - The Pharma Letter
Mineralys Therapeutics (NASDAQ:MLYS) Given Buy Rating at HC Wainwright - Defense World
Mineralys Therapeutics Announces Proposed Public Offering of Common Stock - GlobeNewswire
Mineralys Therapeutics Inc (MLYS) 財務データ
収益
当期純利益
現金流量
EPS
Mineralys Therapeutics Inc (MLYS) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| AKKARAJU SRINIVAS | Director |
Mar 13 '25 |
Buy |
13.50 |
600,000 |
8,100,000 |
5,674,916 |
| RA CAPITAL MANAGEMENT, L.P. | Director |
Mar 13 '25 |
Buy |
13.50 |
1,296,296 |
17,499,996 |
4,280,051 |
| Rodman David Malcom | Chief Medical Officer |
Mar 12 '25 |
Option Exercise |
1.08 |
6,349 |
6,857 |
170,869 |
| Rodman David Malcom | Chief Medical Officer |
Feb 12 '25 |
Option Exercise |
1.08 |
6,348 |
6,856 |
164,520 |
| Levy Adam Scott | CFO and Secretary |
Jan 13 '25 |
Sale |
9.10 |
10,757 |
97,864 |
226,097 |
| Rodman David Malcom | Chief Medical Officer |
Jan 13 '25 |
Option Exercise |
0.84 |
11,367 |
9,567 |
158,172 |
| Congleton Jon | Chief Executive Officer |
Jan 13 '25 |
Sale |
9.06 |
18,333 |
166,082 |
877,608 |
1.66%
4.32%
大文字化:
|
ボリューム (24 時間):